The Contracts Services Team of the University of Pittsburgh's Office of Sponsored Programs is responsible for the review and negotiation of the following non-financial and financial agreements:
Non-financial Agreements
- Confidential Disclosure Agreements (CDAs)/Non-Disclosure Agreements (NDAs)
- Material Transfer Agreements (MTAs) (including repository deposit agreements)
- Data Use Agreements (DUAs)
The Office of Sponsored Programs uses the technology solution MyRA for the web-based development, routing, and submission of non-financial agreements. Note: if a non-financial agreement is related to a federal contract or Other Transaction, it will be processed by the Federal Contracts Services Team.
Financial Agreements
Corporate funded agreements, corporate research agreements, clinical trial agreements, clinical study agreements where the funding source is corporate.
Contact
Phone: 412-624-7400
Email: clincorp@pitt.edu
Hours: M-F 8:30-5:00
Note for Clinical Trials
The Sponsored Clinical Trials & Partnership (SCTP) handles a subset of corporate clinical trials under a formal agreement between the University of Pittsburgh and UPMC for the purpose of facilitating the implementation of industry-initiated and sponsored clinical trials being conducted by Physician Services Division (PSD) or UPMC investigators within the UPMC environment. The purview of the Sponsored Clinical Trials & Partnership (SCTP) with respect to corporate clinical trials is limited to industry-initiated and sponsored clinical trials of drugs and devices conducted within a UPMC or University of Pittsburgh Physicians (UPP) facility or conducted under the direction of a UPMC or UPP staff member in connection with his/her UPMC and/or UPP responsibilities, appointments and clinical privileges, as appropriate.
If the answer to ALL of the following questions is "NO," the clinical trial should be routed to SCTP for processing. Contact the SCTP office at (412) 647-4666 for details.
- Was any University of Pittsburgh faculty or staff member involved substantially in the development of the clinical trial protocol?
- Does any University of Pittsburgh faculty or staff member serve as the investigator-sponsor of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) for the experimental drug or device being evaluated in the clinical trial?
- Is the conduct of this clinical trial being financially supported by any entity other than the industry sponsor and, possibly, the clinical department/division to whom the principal investigator reports?
- Will the clinical trial procedures be performed exclusively within a University facility without any use of UPMC patients, records, or facilities? (this does not apply to University-owned buildings leased by UPMC)
- Does the experimental drug or device being evaluated in the clinical trial 1) emit ionizing radiation; 2) involve a gene transfer intervention; or 3) involve a transgenic xenotransplant?